


# Researchers create a cell therapy based on STAb cells for a type of leukemia with few treatment options

January 16 2023



Comparative in vitro study of engineered CD1a-STAb and CD1a-CAR T cells. (A, B) Schematic diagrams showing the genetic (A) and domain structure (B) of the CD1a-TCE bearing a signal peptide from the human  $\kappa$  light chain signal peptide (S, gray box), the anti-CD1a scFv gene (orange boxes), the anti-CD3 scFv gene (blue boxes), and the Myc and his tags (light yellow box). (C, D) Schematic diagrams showing the genetic (C) and domain structure (D) of the

CD1a-CAR bearing the CD8a signal peptide (S, gray box), the anti-CD1a scFv gene (orange boxes), followed by the human CD8 transmembrane domain and the human 4-1BB and CD3 $\zeta$  endodomains. CD1a-TCE and CD1a-CAR constructs were cloned into a pCCL lentiviral-based backbone containing a T2A-enhanced green fluorescent protein (GFP) cassette (A, C). (E, F) Percentage of reporter GFP (E) and F(ab')<sub>2</sub> (F) expression in CD1a-CAR and CD1a-STAb T cells. One representative transduction out of four independent transductions performed is shown. Numbers represent the percentage of cells staining positive for the indicated marker. (G, H) Percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T cells (G) and percentages of naïve (T<sub>N</sub>), effector memory re-expressing CD45RA (T<sub>EMRA</sub>), central memory (T<sub>CM</sub>), and effector (T<sub>EM</sub>) T cells (H) among non-transduced (NT), or CD1a-CAR and CD1a-STAb transduced T cells. (I) Specific cytotoxicity of NT, CD1a-CAR or CD1a-STAb T cells toward CD1a negative (NALM6) or CD1a positive (MOLT4) cells at the indicated E:T ratios after 24 hours. (J) Alive primary cells from three different coT-ALL patients (P1, P2, P3) after 24 hours co-culture at a 1:1 E:T ratio with NT, CD1a-CAR or CD1a-STAb T cells. (K) Specific cytotoxicity of NT, CD1a-CAR or CD1a-STAb T cells toward NALM6 or MOLT4 cells at 1:4 E:T ratio after 2 and 4 hours. (L) Real-time cell cytotoxicity assay with HEK293T<sup>CD1a</sup> target cells co-cultured with NT, CD1a-CAR or CD1a-STAb T cells at the indicated E:T ratios. Cell index values were determined every 15 min for 80 hours using an impedance-based method. Data from (G–L) is shown as mean $\pm$ SEM of at least three independent experiments by triplicates (n=9). (M) Cartoon depicting target cell death induction by FasL and perforin/granzymes, and how these pathways can be blocked using anti-Fas mAb or EGTA, respectively. (N) Cytotoxicity of MOLT4 cells at 2 and 4 hours (E:T ratio 1:1) and at 24 hours (E:T ratio 1:4) in the presence or absence of anti-Fas mAb or EGTA. Plots show mean $\pm$ SEM of two independent experiments with triplicates (n=6). Statistical significance was calculated by one-way (L) or two-way (G–K, N) ANOVA test corrected with a Tukey's multiple comparisons test (\*p

Citation: Researchers create a cell therapy based on STAb cells for a type of leukemia with few treatment options (2023, January 16) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-01-cell-therapy-based-stab-cells.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.